News

The assistant professor of Hematologic Oncology and Blood Disorders at Atrium Health discussed integrating CAR T therapy into treatment paradigms.

The platform is capable of producing lentiviral vectors for preclinical, clinical, and commercial scales with high titers ranging from 1x10^8 TU/ml to 1x10^9 TU/ml.

The chair of gynecologic oncology at Moffitt Cancer Center gave an overview of a phase 1 trial being conducted at Moffitt Cancer Center.

Review top news and interview highlights from the week ending November 4, 2022.

AlloStem will be evaluated in the CELZ-201 clinical trial for patients with newly diagnosed type 1 diabetes.

Abeona has announced topline results from its phase 3 VIITAL study of EB-101.

Updated data from the ALTITUDE trial were presented at the 55th ARS meeting in Pasadena, CA.

Data from the first 2 patients were presented at the IWWM 2022 meeting.

Neurotech has announced updated data from protocol A and B phase 3 studies.

The chair of gynecologic oncology at Moffitt Cancer Center discussed advantages of targeting follicle stimulating hormone receptor with cell therapy for ovarian cancer.

The DSMB has recommended the trial to continue with additional risk mitigation procedures.

The medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.

Studies have demonstrated positive data that suggest in vivo gene editing will be the future treatment paradigm for retinal diseases.

Cellular Biomedicine group developed the therapy after efficacy was seen with Iovance’s lifilecuel in solid tumor studies.

The pediatrician from Royal Manchester Children’s Hospital discussed how further research in Gaucher disease can benefit the field of rare lysosomal diseases as a whole.

The chief executive officer of Chimera Bioengineering discussed CBIO-007 and its planned IND submission for colorectal and triple negative breast cancer.

Review top news and interview highlights from the week ending October 28, 2022.

CGTLive highlights the PROVIDE trial of PR001 for Gaucher Awareness Month.

The chief scientific officer of Excision BioTherapeutics discussed the phase 1/2 clinical trial of the CRISPR gene editing therapy.

The trial expects to enroll its first patient in the first half of 2023.

The decision comes after strategic uncertainty regarding a review of preliminary clinical data from GSK’s lete-cel product candidate trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The pediatrician from Royal Manchester Children’s Hospital discussed progress with the PROVIDE trial of PR001.

Cells produced by this method were also shown to be more potent in animal models than cells made with typical processes.

The trial is being conducted at the University of California – San Diego under the leadership of Stephanie Cherqui, PhD.

As we learn more about genomics and identify more genes tied to rare disorders, the role of genetic counselors will become even more critical.

The decision comes after a previous clinical hold delayed key medical milestones in the KEYNOTE-B79 trial.

The grant goes toward developing an innovative approach to gene-agnostically and autonomously regulate pressure.